TransCode Therapeutics, Inc. (BOATS:RNAZ) Financings
Financings
| Raise | Date |
|---|---|
| Strategic investment of non-voting Series B convertible preferred stock Announced: US$25M · Tungsten Advisors Dealers: Tungsten Advisors (lead) Buyers: CK Life Sciences Int'l., (Holdings) Inc. (subsidiary) (223.7337 shares of Series B Preferred Stock for $25 million; approximately 91% fully diluted together with the acquisition) Use of proceeds: Primarily to advance clinical development of lead microRNA asset TTX-MC138 into a Phase 2 clinical trial | Oct 9, 2025 |
| Registered direct offering of shares of common stock and warrants Closed: US$10M raised · US$0.98 a share · Warrants at US$0.86 for 60 months · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Product development, including clinical trials of TTX-MC138 and IND-enabling studies, plus working capital and general corporate purposes | Mar 25, 2025 |
| Private placement of shares of common stock with Series C and Series D warrants Update: about US$8M · US$0.377 a share · Warrants at US$0.475 for 60 months · The Benchmark Company, LLC Dealers: The Benchmark Company, LLC (lead) Use of proceeds: General corporate purposes and working capital | Feb 25, 2025 |